Sugi Predict

Sugi Predict / Compounds / SCHEMBL354988

SCHEMBL354988

SCHEMBL354988

Cc1ccc2c(c1)C(=O)CC2

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PBRM1 Q86U86 1/20 0.59
▸ PARP10 Q53GL7 2/20 0.56
▸ PARP1 P09874 1/20 0.56
▸ BRD4 O60885 2/20 0.49
▸ METAP1 P53582 2/20 0.48
▸ ACHE P22303 1/20 0.48
▸ TYMS P04818 2/20 0.46
▸ MAOA P21397 2/20 0.46
▸ MAOB P27338 2/20 0.46
▸ CYP19A1 P11511 2/20 0.45
▸ CYP11B2 P19099 2/20 0.45
▸ CASP1 P29466 1/20 0.44
▸ CASP7 P55210 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ PARP11 Q9NR21 1/20 0.43
▸ PTGS2 P35354 1/20 0.42
▸ ELANE P08246 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30465799 1.00 PBRM1 (0.59) PBRM1PARP10PARP1BRD4METAP1
SCHEMBL21234894 0.88 METAP1 (0.55) PBRM1PARP10PARP1BRD4METAP1
SCHEMBL29673118 0.88 MAOA (0.59) PBRM1PARP10PARP1METAP1ACHE
SCHEMBL1274936 0.88 MAOA (0.59) PBRM1PARP10PARP1METAP1ACHE
SCHEMBL10177012 0.88 MAOA (0.59) PBRM1PARP10PARP1METAP1ACHE
SCHEMBL14925847 0.84 METAP1 (0.60) PARP10PARP1METAP1ACHETYMS
SCHEMBL5208267 0.84 BRD4 (0.55) PBRM1PARP10PARP1BRD4TYMS
SCHEMBL5929505 0.83 CYP2A6 (0.58) PBRM1PARP10PARP1BRD4METAP1
SCHEMBL29726014 0.83 CASP1 (0.59) PBRM1PARP10PARP1METAP1MAOA
SCHEMBL423287 0.83 CASP1 (0.59) PBRM1PARP10PARP1METAP1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113861113-B Preparation and application of fused ring pyridine compound and derivative thereof 中国科学院福建物质结构研究所 2022-12-06 — — CN claimed
CN-113861113-A Preparation and application of fused ring pyridine compound and derivative thereof 中国科学院福建物质结构研究所 2021-12-31 — — CN claimed
CN-112574078-A 2-sulfuryl-2, 3-dihydro-1-indanone and derivatives and synthesis method thereof 湖南工程学院 2021-03-30 — — CN claimed
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 — — US claimed
US-10043978-B2 Organic semiconductor formulations FLEXTERRA, INC. (US) 2018-08-07 — — US claimed
US-20170012208-A1 ORGANIC SEMICONDUCTOR FORMULATIONS USINVEST LLC 2017-01-12 — — US claimed
US-20260068882-A1 ARTHROPOD CONTROLLING COMPOSITION FIRMENICH & CIE (CH) 2026-03-12 — — US disclosed
US-12441748-B2 Metal-ligand complexes DOW GLOBAL TECHNOLOGIES LLC (US) 2025-10-14 — — US disclosed
CN-113748140-B Metal-ligand complexes 陶氏环球技术有限责任公司 2025-03-11 — — CN disclosed
CN-119462458-A Covalent inhibitor of targeted hCES A and preparation method and application thereof 中国人民解放军海军军医大学 2025-02-18 — — CN disclosed
US-20240150293-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS VERNALIS (R&D) LTD (GB) 2024-05-09 — — US disclosed
EP-4277892-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS Les Laboratoires Servier (FR) 2023-11-22 — — EP disclosed
US-20230339947-A1 USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS Madera Therapeutics, LLC 2023-10-26 — — US disclosed
EP-0302591-B1 NITRILO (TRIS) POLYOXYALKYLENEAMINES IN A REACTION INJECTION MOLDING PROCESS TEXACO DEVELOPMENT CORPORATION (US) 1993-03-24 — — EP disclosed
EP-0528553-A1 Tetrahydroisoquinoline derivatives, processes for producing the same and fungicides containing the same TOSOH CORPORATION (JP) 1993-02-24 — — EP disclosed
US-4827039-A AUTOMOBILE BODY PARTS TEXACO INC. (US) 1989-05-02 — — US disclosed
EP-0302591-A2 Nitrilo (tris) polyoxyalkyleneamines in a reaction injection molding process TEXACO DEVELOPMENT CORPORATION (US) 1989-02-08 — — EP disclosed
US-4357337-A PIPERIDINYLALKYL DERIVATIVES PHARMINDUSTRIE (FR) 1982-11-02 — — US disclosed
EP-0022519-B1 PROCESS FOR THE PREPARATION OF A MIXTURE OF 2-HYDROXY AND 4-HYDROXY BENZYL ALCOHOL BAYER AG (DE) 1982-02-03 — — EP disclosed
EP-0022519-A1 Process for the preparation of a mixture of 2-hydroxy and 4-hydroxy benzyl alcohol BAYER AG (DE) 1981-01-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260068882-A1 ARTHROPOD CONTROLLING COMPOSITION CNOT9, MSL1, MT-CO2 PBRM1 3503/4885PARP10 4527/4885PARP1 4749/4885
US-20240150293-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS BCL2, BAX, BCL2A1 PBRM1 2816/4885PARP10 505/4885PARP1 201/4885
US-12441748-B2 Metal-ligand complexes ARL1, CRKL, SAAL1 PBRM1 3504/4885PARP10 479/4885PARP1 1727/4885
US-20230339947-A1 USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS CLPP, PRCP, PREP PBRM1 2555/4885PARP10 3165/4885PARP1 1785/4885
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR PBRM1 2382/4885PARP10 4841/4885PARP1 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.